|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
CO-ADMINISTRATION WITH CORTICOSTEROIDS MAY INCREASE THE RISK OF HYPOKALEMIA
|
CORTICOSTEROIDS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CORTICOSTEROIDS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CORTICOSTEROIDS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
ANTAGONISE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CONCURRENT USE MAY REDUCE THE EFFICACY OF SERMORELIN
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
CORTICOSTEROIDS CAN AFFECT THE RESPONSE OF ITS THERAPY
|
CORTICOSTEROIDS IF USED CONCOMITANTLY MAY LEAD TO PULMONARY EDEMA
|
CORTICOSTEROIDS CAN CAUSE HYPOKALEMIA OR HYPOMAGNESEMIA AND POTASSIUM OR MAGNESIUM DEPLETION CAN SENSITIZE THE MYOCARDIUM TO DIGOXIN RESULTING IN DIGTALIS TOXICITY
|
CORTICOSTEROIDS CAN CAUSE HYPOKALEMIA OR HYPOMAGNESEMIA AND POTASSIUM OR MAGNESIUM DEPLETION CAN SENSITIZE THE MYOCARDIUM TO DIGOXIN RESULTING IN DIGTALIS TOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS AND RENAL SIDE EFFECTS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
AMIODARONE SHOULD BE USED WITH CAUTION WITH DRUGS THAT INDUCE HYPOKALEMIA AND /OR HYPOMAGNESEMIA
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|